<DOC>
	<DOCNO>NCT00201318</DOCNO>
	<brief_summary>* AIMS OF THE STUDY ( STUDY OBJECTIVES ) 1 . To test effect daily lamivudine ( 100 mg ) reduce risk HBV reactivation hepatitis development HBsAg ( + ) NHL patient . 2 . To test efficacy daily lamivudine prevent treat hepatitis B reactivation circumvent hepatic failure death . 3 . To test whether lamivudine improve overall outcome NHL patient HBV carrier . ( Study end-points : The major end-point : hepatitis B reactivation NHL patient -- -defined high 10-fold increase serum HBV DNA level and/or reappearance HBeAg serum within 6 month chemotherapy . The minor end-point I : event hepatic failure death -- -defined jaundice hepatic encephalopathy . The minor end-point II : response rate survival rate HBsAg-positive NHL patient receive lamivudine prophylaxis treatment . )</brief_summary>
	<brief_title>A Randomized Study Non-Hodgkin 's Lymphoma Patients Carrying Hepatitis B Surface Antigen</brief_title>
	<detailed_description>- TREATMENT PLANS 1 . Systemic chemotherapy CHOP regimen Schedule Dose CHOP Cyclophosphamide 750 mg/m2 i.v . Day 1 Doxorubicin 50 mg/m2 i.v . Day 1 Vincristine 1.4 mg/m2/d i.v . Day 1 Prednisolone 60 mg/m2/d p.o . Day 1-7 1.1 Courses repeat every 21 day . 1.2 For patient CR , give least 2 additional course minimum 6 course . 1.3 For patient maximal response PR SD , change second-line chemotherapy . The regimens second-line chemotherapy discretion investigator . Local radiotherapy allow residual localize 1.4 For patient PD , change second-line chemotherapy . The regimen latter discretion investigator . 2.1 Arm I Patients take lamivudine 100 mg P.O . qd , start Day 1 first course CHOP , 2 month completion chemotherapy . Lamivudine maintain matter hepatitis occur chemotherapy . If second-line chemotherapy use , lamivudine dose schedule continue 2 month completion second-line chemotherapy . If third-line chemotherapy need , use lamivudine 2.2 Arm II Patients treat CHOP alone . If patient develop clinical hepatitis , define section 7.2 , lamivudine 100 mg , P.O. , qd. , give , continue hepatitis resolve . Prophylactic lamivudine give subsequent chemotherapy . ( Our previous study indicate nearly clinical hepatitis develop HBV carrier systemic chemotherapy cause HBV reactivation . Therefore , practical reason , investigator advise wait result HBV DNA serology examination start lamivudine treatment . ) 3.0 DOSE MODIFICATION 3.1 Hematological Toxicity* Drug administration postpone full hematological recovery ( AGC ＞ 2,000/mm3 Platelet ＞ 100,000/mm3 ) prior course scheduled treatment day . Full dose give soon hematological recovery document . If two week due day recovery still incomplete , treatment may start dosage reduce accord follow schedule : AGC*/mm3Platelet/mm3 1,500-2,00075,000-100,000 1,000-1,49950,000-74,999 ＜1,000＜50,000 Cyclophosphamide 80 % 60 % ** Doxorubicin 80 % 60 % ** - G-CSF allow use prophylactically old ( &gt; 60 year old ) patient patient previous ongoing prolonged myelosuppression . - Postpone another week . If count remain AGC＜1,500 Platelet ＜75,000 three week due day , patient study . 3.2 Hepatotoxicity For patient normal prechemotherapy serum ALT , hepatitis flare-up defined ALT elevation great 1.5 fold upper normal limit . For patient abnormal prechemotherapy serum ALT , hepatitis flare-up define 2.0 fold great increase serum ALT level . The hepatitis hepatitis flare-up attributed reactivation HBV sudden elevation ( ＞10-fold ) serum HBV DNA level reappearance HBV DNA and/or HBeAg serum . Since result previous study indicate nearly clinical hepatitis develop HBV carrier chemotherapy cause HBV reactivation , serum HBV DNA data readily available hospital , patient hepatitis flare-up consider HBV reactivation prove otherwise . For patient second arm , biochemical hepatitis prompt start daily lamivudine , even definite documentation 10-fold increase HBV DNA . For patient minor hepatic dysfunction ( total bilirubin ＜3.0 mg/dl ALT ＜200 I.U./L ) , full-dose chemotherapy recommend scheduled treatment day without delay . For patient severe hepatic dysfunction ( total bilirubin ≧ 3.0 mg/dl ALT ≧ 200 I.U./L ) , subsequent course postpone 1 week dosage modify following value remain abnormal 1 week : Total Bilirubin ( mg/dl ) ＜3.0 3.0 ~ 4.9 5.0 ~ 7.5 ＞7.5 ALT ( I.U./L ) ＜200 200 ~ 399 400 ~ 800 ＞800 Doxorubicin 100 % 75 % 50 % * - Wait recovery serum level value . Patients study Bil ＞ 7.5 mg/dl ALT ＞ 800 I.U/L , 3 week due day . 3.3 Gastrointestinal Toxicity In case severe ( ≧ NCI Gr III ) anorexia , nausea , vomit , diarrhea , stomatitis abdominal pain , therapy delay improvement symptom ≦ GrII . Patients study ≧ Gr III toxicity persist ≧ 3 week due day . Patients allow use H3-blockers subsequent course severe nausea vomiting . If gastrointestinal toxicity still ≧ Gr III next course , dose cyclophosphamide doxorubicin reduce 25 % subsequent course . If episode severe reaction , dos escalate , 12.5 % time , back 100 % . 3.4 Cardiotoxicity In case NCI grade II cardiotoxicity , doxorubicin reduce 50 % . If cardiotoxicity resolve , dose may carefully deescalated , 12,5 % time , subsequent course . If severe ( ≧ NCI grade III ) cardiotoxicity develop , doxorubicin discontinue used subsequent course . 3.5 Multiple Toxicity In event multiple toxicity , dose modification base guideline require great reduction dos . 4.0 CRITERIA FOR REMOVAL FROM STUDY All patient still complete protocol treatment ( 1st-line 2nd-line ) continuously followed-up study end point . Patients remove study major violation protocol due follow reason : 1 . Completion assign therapy observation . 2 . Progressive disease . 3 . Excessive complication toxicity . 4 . Patient death . 5 . Patient withdrawal refusal . 5.0 MEASUREMENT OF EFFECT ： Authorized physicians research nurse must call Ms. Yueh-Ling Ho TCOG Operations Office ( Tel : 02-26534401 ext 6655 ) patient registration randomization . A permuted block randomization use generate list Statistical Center house Division Biostatistics , NHRI . Treatment assignment give patient pass eligibility check . 6.0 REPORT OF ADVERSE EFFECT : Adverse effect treatment report TCOG Operations Office 02-26534401 ext 6655 , 6657 , 6658 FAX : 02-2782-3755 , within 48 hour . See appendix TCOG ADR ( Adverse Drug Reaction ) Form report adverse effect .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>1 . Histologically proven NHL , intensive chemotherapy consider treatmentofchoice . 2 . HBsAgpositive . 3 . No previous chemotherapy radiotherapy , concurrent radiotherapy . 4 . AGC ≧ 2,000/mm3 , Platelet ≧ 100,000/mm3 peripheral blood . 5 . Total bilirubin ＜ 2.5 mg/dl . Alanine aminotransferase ( SGPT ) ＜ 200 I.U./L 6 . Serum creatinine ≦1.5 mg/dl Blood urea nitrogen ( BUN ) ≦ 25 mg/dl 7 . Objectively measurable valuable disease 8 . Signed informed consent 1 . Age ＞ 75 year old , Age ＜ 15 year old 2 . Pregnant breastfeed woman . 3 . Patients history brain metastasis CNS involvement . 4 . Child 's class B C patient liver cirrhosis . 5 . Impaired cardiac function NYHA ( New York Heart Association ) classification ≧ Gr II .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>